Equity to Asset ratio is calculated as total stockholders equity divided by total asset. PW Medtech Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$4,423.6 Mil. PW Medtech Group's Total Assets for the quarter that ended in Dec. 2023 was HK$5,635.2 Mil.
Therefore, PW Medtech Group's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.79.
The historical rank and industry rank for PW Medtech Group's Equity-to-Asset or its related term are showing as below:
HKSE:01358'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.79 Med: 0.88 Max: 0.97
Current: 0.79
During the past 12 years, the highest Equity to Asset Ratio of PW Medtech Group was 0.97. The lowest was 0.79. And the median was 0.88.
HKSE:01358's Equity-to-Asset is ranked better than 73.5% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs HKSE:01358: 0.79
PW Medtech Group Equity-to-Asset Historical Data
The historical data trend for PW Medtech Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PW Medtech Group's Equity-to-Asset
For the Medical Instruments & Supplies subindustry, PW Medtech Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group's Equity-to-Asset Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's Equity-to-Asset falls into.
PW Medtech Group Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
PW Medtech Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PW Medtech Group (HKSE:01358) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
PW Medtech Group Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of PW Medtech Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
PW Medtech Group (HKSE:01358) Business Description
PW Medtech Group Ltd is a medical device company with a focus on fast-growing and high-margin segments of China's medical device industry. The company is engaged in the research and development, manufacturing, and sale of the advanced infusion set, intravenous cannula products, and insulin needles. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, and insulin needles and pens. The company operates through three business segments: Infusion Set Business; Blood Purification Business; and Regenerative Medical Biomaterials Business.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01358 has been successfully added to your 